Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2018-07-13 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
简式权益变动报告（二）
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告" which translates to a "Simplified Equity Change Report." It details the change in shareholding of 福安药业（集团）股份有限公司, specifically the transfer of shares from a controlling shareholder to an employee stock ownership plan. The document includes detailed information about the share transfer agreement, the number of shares transferred, the price, the conditions of the transfer, and the legal compliance statements. It also references relevant Chinese securities laws and regulations governing equity changes and disclosures. The document is not an annual report, earnings release, or management discussion but a formal disclosure of a change in significant shareholding. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length (9033 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2018-07-13 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is titled as "Independent Directors' Opinions" regarding specific matters discussed at the 21st meeting of the third board of directors of the company. It contains independent directors' opinions on employee stock ownership plans, use of surplus raised funds to supplement working capital, and guarantees for subsidiaries' financing. The document references compliance with relevant laws and stock exchange rules, and includes signatures of independent directors. It does not contain financial statements or detailed financial data, nor is it a full report like an annual or interim report. It is a formal opinion document related to board meeting matters, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories such as Board/Management Information (MANG) which is for announcements of changes in board or management, or Proxy Solicitation (PSI) which is for materials sent to shareholders for voting. The document is also short (1594 characters) and is not a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2018-07-13 Chinese
第一期员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary (草案) of an employee stock ownership plan (员工持股计划) for 福安药业 (Fuan Pharmaceutical). It includes legal references, plan purpose, participants, funding sources, stock sources, plan duration, management, voting procedures, and other operational details. It is not a financial report, earnings release, or regulatory announcement but a comprehensive plan document outlining the structure and rules of the employee stock ownership plan. This type of document fits best under Capital/Financing Update (CAP) because it relates to company financing activities through employee stock ownership plans and capital structure changes. The document length (9893 characters) and content confirm it is the plan itself, not just an announcement or summary, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2018-07-13 Chinese
第一期员工持股计划（草案）
Capital/Financing Update Classification · 95% confidence The document is titled "福安药业第一期员工持股计划（草案）" which translates to "Fuan Pharmaceutical First Employee Stock Ownership Plan (Draft)". It is a detailed draft plan for an employee stock ownership plan (ESOP) including purpose, principles, participants, funding, stock sources, duration, management, rights and obligations, and procedures for implementation and governance. It references relevant laws and regulations such as the Company Law, Securities Law, and specific regulatory guidance on employee stock ownership plans. The document is comprehensive and lengthy (over 14,000 characters), containing detailed procedural and governance information about the employee stock ownership plan. It is not a financial report, earnings release, or a simple announcement. It is not a proxy solicitation or voting results announcement. It is a detailed plan document related to capital structure and financing activities, specifically an employee stock ownership plan involving share transfers and funding arrangements. Therefore, the document best fits the category of Capital/Financing Update (CAP), as it provides an update and detailed plan on a capital-related financing activity (employee stock ownership plan).
2018-07-13 Chinese
国都证券股份有限公司关于公司将结余募集资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from a sponsoring securities company regarding the permanent supplementary use of surplus raised funds as working capital by a listed company. It references regulatory rules related to the use of raised funds, details the amount of funds raised, their usage, surplus, and the approval process by the board, supervisory committee, and independent directors. The document is a verification or audit opinion on the use of raised funds rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not an announcement of voting results or a proxy statement. The document is a specialized audit or verification report related to compliance with fundraising regulations and fund usage. Therefore, it fits best under Audit Report / Information (AR). The document length is 2737 characters, which is consistent with a detailed audit opinion rather than a brief announcement or a full annual/interim report. FY 2018
2018-07-13 Chinese
关于为全资子公司申请银行授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 福安药业（集团）股份有限公司 regarding the provision of guarantees for bank credit facilities applied for by its wholly-owned subsidiaries. It details the guarantee amounts, collateral (land and property mortgages), financial data of the subsidiaries, and approvals from the board and independent directors. There is no indication that this is a financial report, earnings release, or management discussion. The document is focused on a financing-related guarantee announcement, describing the company's capital/financing activities and related approvals. It is not a full financial report or audit report but an update on financing guarantees. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4467 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement. Hence, the classification is CAP with high confidence.
2018-07-13 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.